Wednesday, May 20, 2020
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate. "We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx™ Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."
"We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine," commented Chris Cappello, President and CEO, PharmaJet, "Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings."
